Prisma Capital Partners’s Elevance Health ELV Stock Holding History

Prisma Capital Partners’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-18,900	Closed	-$4.15M	–	15
2018 Q1	$4.15M	Hold	18,900	–	–	2.88%	9
2017 Q4	$4.25M	Sell	18,900 -18,000	-49%	-$3.83M	4.01%	9
2017 Q3	$7.01M	Hold	36,900	–	–	7.55%	4
2017 Q2	$6.94M	Buy	+36,900	New	+$6.63M	10.59%	3

Other funds holding ELV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Prisma Capital Partners's ELV Position: Q2 2018 in Review

Prisma Capital Partners sold out of Elevance Health (ELV) in Q2 2018, closing a stake of 18,900 shares — an estimated $4.15M sold.

Prisma Capital Partners first reported a position in ELV in Q2 2017 and held it in 4 quarters. The position peaked at $7.01M in Q3 2017. 935 funds tracked by Wall St. Rank hold ELV as of Q2 2018.

Prisma Capital Partners reported no remaining Elevance Health position as of Q2 2018 after selling out during the quarter.
Prisma Capital Partners sold 18,900 Elevance Health shares in Q2 2018, an estimated $4.15M.
Prisma Capital Partners first reported a position in Elevance Health in Q2 2017 and held it in 4 quarters.
Prisma Capital Partners's Elevance Health position peaked at $7.01M in Q3 2017.
935 funds tracked by Wall St. Rank held Elevance Health as of Q2 2018.

Based on Prisma Capital Partners's 13F filing for Q2 2018, filed 13 Aug 2018.